首页> 外文OA文献 >2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

【2h】

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

机译：2.2用新型IL-1β封闭单克隆抗体canakinumab进行的II期临床试验，评估系统性幼年特发性关节炎（sJIA）儿童的初步剂量，安全性和疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features [J] . Arthritis and Rheumatism . 2012,第2期

机译：II期，多中心，开放标签的研究，评估canakinumab在具有活跃系统特征的系统性幼年特发性关节炎中的剂量，初步安全性和有效性
2. Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study [J] . N Ruperto, H Brunner, G Horneff, Pediatric rheumatology online journal . 2011,第S1期

机译：Canakinumab（一种长效的全人类抗白介素-1β抗体）在具有活跃系统特征的系统性幼年特发性关节炎中的功效和安全性：III期研究的结果
3. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study [J] . Rieke Alten, Juan Gomez-Reino, Patrick Durez, BMC Musculoskeletal Disorders . 2011,第1期

机译：人类抗IL-1β单克隆抗体canakinumab在类风湿关节炎中的功效和安全性：一项为期12周的II期剂量研究的结果
4. 2.2 A phase II trial with canakinumab a new IL-1beta blocking monoclonal antibody (ACZ885) to evaluate preliminary dosing safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) [O] . N Ruperto, P Quartier, N Wulffraat, 2008

机译：2.2用新型IL-1β封闭单克隆抗体canakinumab进行的II期临床试验评估系统性幼年特发性关节炎（sJIA）儿童的初步剂量安全性和疗效
5. 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) [O] . Ruperto, N, Quartier, P, Wulffraat, N, 2008

机译：2.2用新型IL-1β封闭单克隆抗体canakinumab进行的II期临床试验，评估系统性幼年特发性关节炎（sJIA）儿童的初步剂量，安全性和疗效

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

著录项

引文网络

相似文献

相关主题

期刊订阅